by Genentech, that examined the records of 78,000 Medicare patients who had taken Avastin or Lucentis for AMD. According to an abstract of that study released earlier this month, people taking Avastin had an 11% higher risk of overall mortality and...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Study Compares Lucentis, Avastin
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account